Evommune (NYSE:EVMN) Now Covered by Oppenheimer

Stock analysts at Oppenheimer started coverage on shares of Evommune (NYSE:EVMN) in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. The brokerage set an “outperform” rating and a $42.00 price target on the stock. Oppenheimer’s price target indicates a potential upside of 107.31% from the company’s previous close.

A number of other research firms also recently weighed in on EVMN. Raymond James Financial began coverage on Evommune in a report on Wednesday, January 7th. They set a “strong-buy” rating and a $40.00 target price for the company. HC Wainwright initiated coverage on shares of Evommune in a report on Tuesday, January 6th. They issued a “buy” rating and a $35.00 target price on the stock. Wall Street Zen raised Evommune from a “sell” rating to a “hold” rating in a research note on Sunday, December 14th. The Goldman Sachs Group raised Evommune to a “buy” rating in a research note on Wednesday, January 7th. Finally, William Blair initiated coverage on shares of Evommune in a research note on Monday, December 1st. They set an “outperform” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Evommune has a consensus rating of “Buy” and an average price target of $39.17.

Evommune Trading Up 7.5%

EVMN stock opened at $20.26 on Thursday. Evommune has a 1-year low of $13.89 and a 1-year high of $24.03. The company has a market capitalization of $638.60 million and a price-to-earnings ratio of -2.51. The business’s 50-day simple moving average is $18.51.

Evommune (NYSE:EVMN) last issued its quarterly earnings results on Thursday, December 11th. The company reported ($8.07) earnings per share for the quarter, missing the consensus estimate of ($6.58) by ($1.49). The firm had revenue of $10.00 million for the quarter, compared to the consensus estimate of $10.00 million.

Hedge Funds Weigh In On Evommune

A hedge fund recently bought a new stake in Evommune stock. Capricorn Fund Managers Ltd acquired a new position in Evommune, Inc. (NYSE:EVMN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 60,000 shares of the company’s stock, valued at approximately $1,027,000. Capricorn Fund Managers Ltd owned approximately 0.19% of Evommune as of its most recent filing with the Securities and Exchange Commission.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.